Psychedelics have shown promise in easing the emotional and existential distress of terminally ill patients, offering a potential path to peace and acceptance as they face the end of life. Yet, the federal illegality of these substances in the U.S. restricts access, leaving many patients without this vital option for end-of-life care. “Psilocybin has an impact on serotonin receptors in the brain that causes changes in perception and insights that assist patients in dealing with their fears and feelings in a new way,” says Dr. Bryan Bruno, Medical Director at Mid City TMS.